Cilengitide in Treating Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying how well cilengitide works in treating patients
with metastatic prostate cancer. Cilengitide may stop the growth of prostate cancer by
blocking blood flow to the tumor